Opdivo (Nivolumab)

Overview
Opdivo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer. Opdivo is often prescribed with ipilimumab (Yervoy). Opdivo is also known by… read more

Opdivo Qvantig (Nivolumab and Hyaluronidase-Nvhy)

Overview
Opdivo Qvantig is approved by the U.S. Food and Drug Administration (FDA) as part of a treatment regimen for non-small cell lung cancer (NSCLC) in certain scenarios. These include use in combination with…

Portrazza (Necitumumab)

Overview
Portrazza is approved by the U.S. Food and Drug Administration (FDA) for use in combination with the chemotherapy drugs gemcitabine and cisplatin for the first-line treatment of metastatic squamous non-small cell…

Retevmo (Selpercatinib)

Overview
Retevmo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, rearranged-during-transfection (RET) fusion-positive, non-small cell lung cancer. Retevmo… read more

Rozlytrek (Entrectinib)

Overview
Rozlytrek is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by an… read more

Rybrevant (Amivantamab-Vmjw)

Overview
Rybrevant is approved by the U.S. Food and Drug Administration (FDA) for the treatment of lung cancer. It is specifically indicated for adults with locally advanced or metastatic non-small cell lung cancer…

Rybrevant Faspro (Amivantamab and Hyaluronidase-Lpuj)

Overview
Rybrevant Faspro is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic (advanced) non-small cell lung cancer (NSCLC) that has specific…

Tabrecta (Capmatinib)

Overview
Tabrecta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic, non-small cell lung cancer whose tumors have a mutation known as mesenchymal-epithelial… read more

Tafinlar (Dabrafenib)

Overview
Tafinlar is a brand name for the drug Dabrafenib, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of individuals with metastatic non-small cell lung cancer (NSCLC) with the BRAF…

Tagrisso (Osimertinib)

Overview
Tagrisso is approved by the U.S. Food and Drug Administration (FDA) for several indications related to non-small cell lung cancer (NSCLC). It is used as an adjuvant therapy (additional treatment following…

Taxotere (Docetaxel)

Overview
Taxotere is approved by the U.S. Food and Drug Administration (FDA) for use as a treatment for non-small cell lung cancer (NSCLC), along with other types of cancer. Taxotere is typically prescribed when prior…

Tecentriq (Atezolizumab)

Overview
Tecentriq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with small cell or non-small cell lung cancer by itself or as an adjuvant therapy (in combination with… read more

Tecentriq Hybreza (Atezolizumab and Hyaluronidase-Tqjs)

Overview
Tecentriq Hybreza, a combination of atezolizumab and hyaluronidase, is approved by the U.S. Food and Drug Administration (FDA) for treating various forms of lung cancer, including non-small cell lung cancer…

Tepmetko (Tepotinib)

Overview
Tepmetko is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) who have MET exon 14 skipping alterations, as confirmed by a…

Vinorelbine

Overview

Vinorelbine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC). It may be prescribed either in combination with cisplatin for patients with locally…

Vitrakvi (Larotrectinib)

Overview
Vitrakvi is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance… read more

Vizimpro (Dacomitinib)

Overview
Vizimpro is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21… read more

Xalkori (Crizotinib)

Overview
Xalkori is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer (NSCLC) with tumors that are positive for anaplastic lymphoma kinase (ALK) as… read more

Yervoy (Ipilimumab)

Overview
Yervoy is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic non-small cell lung cancer with tumors that express the protein PD-L1. Yervoy is prescribed in… read more

Zegfrovy (Sunvozertinib)

Overview
Zegfrovy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific mutations (changes) in the…

Zepzelca (Lurbinectedin)

Overview
Zepzelca is approved by the U.S. Food and Drug Administration (FDA) for treating adults with metastatic (advanced) small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based…

Zykadia (Ceritinib)

Overview
Zykadia is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are positive for anaplastic lymphoma kinase… read more